期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

ARB类药物对颈动脉内膜中层厚度影响的网状Meta分析

The Effect of Angiotensin Ⅱ Receptor Blockers on Carotid Intima Media Thickness: A network Meta-Analysis of Randomized Controlled Trials
下载PDF
导出
摘要 目的:评价血管紧张素抑制剂(ARBs)改善颈动脉内膜中层厚度(CIMT)的疗效。方法:计算机系统检索Pub Med、the Cochrane Database、Web of Science、CMCC和CBM数据库截止到2013年12月关于CIMT的RCT研究,采用ADDIS软件(1.16.5)对ABRs改善CIMT的结果进行合并分析。结果:共纳入17项研究,meta分析结果显示:ARBs药物组的CIMT较对照组均有明显的改善,且具有统计学意义;替米沙坦改善CIMT的作用强于坎地沙坦[0.10(0.01,0.23)],具有统计学意义;ARBs改善CIMT的顺序为替米沙坦、缬沙坦、厄贝沙坦、氯沙坦和坎地沙坦。结论:在ARBs类药物之间,改善CIMT的疗效具有明显差异。 Objective： To assess the effect of Angiotensin II Receptor Blockers（ABRs）on carotid intima-media thickness（CIMT）. Methods： The Pub Med, the Cochrane Database, Web of Science, CMCC, and CBM were searched for articles published until December 2013. The related data were analyzed by ADDIS（1.16.5） software.Results： There were 17 randomized controlled trials listed in five databases. There was a significant CIMT decrease with ARBs compared to placebo. The CIMT decrease with telmisartan was greater than with Candesartan [0.10（0.01,0.23）]. The effect of ARBs on carotid intima media thickness in sequence from high to low was telmisartan,valsartan, irbesartan, losartan to candesartan. Conclusion： Among ARBs, there is a marked different effect on CIMT.
作者 李超鹏 赵洁 徐梅
机构地区 石河子大学医学院第一附属医院药剂科
出处 《农垦医学》 2014年第4期289-293,共5页 Journal of Nongken Medicine
基金 石河子大学医学院第一附属医院基金项目(SS2011-090)
关键词 网状Meta分析 血管紧张素抑制剂 颈动脉内膜中层厚度 Network Meta-Analysis Angiotensin II Receptor Blockers Carotid Intima-Media Thickness
分类号 R972 [医药卫生—药品]
  • 相关文献

参考文献14

  • 1Riccioni G. The effect of antihypertensive drugs on carotid intima media thickness: an up-to-date review [J]. Current Medicinal ChemistryCurr Med Chem, 2009,16(8):988-996.
  • 2Sonoda M, Aoyagi T, Takenaka K, et al. A one-year study of the antiatherosclerotic effect of the angiotensin-ll receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors [J]. Int Heart J, 2008,49(1):95-103.
  • 3Baguet JP, Asmar R, Valensi P, et al. Effects of candesartan cilexetiI on carotid remodeling in hypertensive diabetic patients: the MITEC study [J]. Vasc Health Risk Manag, 2009,5(1): 175-183.
  • 4Yamamoto K, Ozaki H, Takayasu K, et al. The effect of losartan and amlodipine on left ventricular diastotic function and atheroselerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study [J]. Hypertens Res, 2011,34(3):325-330.
  • 5Kinouchi K, Ichihara A, Sakoda M, et al. Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients [J]. Kidney Blood Press Res, 2010,33(4):304-312.
  • 6lasegawa H, Takano H, Narumi H, et al. Effects of telmisar- tan and losartan on cardiovascular protection in Japanese hyp- ertensive patients[J].Hypertens Res, 2011,34(11): 1179-1184.
  • 7Lethen H,Tries HP, Kersting S, et al. Improvement of coronary mierovascular function after Angiotensin receptor blocker treatment with irbesartan in patients with systemic hypertension [J]. J Clin Hypertens (Greenwich),2011,13(3): 155-161.
  • 8Mortsell D, Malmqvist K, Held, C, et al. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventrieular Hypertrophy Investigation versus Atenolol (SILVHIA) study [J]. J Intern Med,2007,261(5):472-479.
  • 9~edeseo MA, Natale F, Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients [J]. J Clin Hypertens (Greenwich), 2006,8(9):634-641.
  • 10张明辉,杨玉斌,赵杰.氯沙坦与依那普利对高血压患者颈动脉内膜中层厚度的影响[J].医学临床研究,2011,28(3):544-545. 被引量：1

二级参考文献34

  • 1陈名道.糖尿病与冠心病——同源病,等危症?[J].中华内分泌代谢杂志,2006,22(1):4-6. 被引量：53
  • 2De Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology, X X Ⅲ: the angiotensin Ⅱ: receptors. Pharmacol Rev, 2000,52:415-472.
  • 3Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenotol. Lancet, 2002,359:995-1003.
  • 4Henriksen EJ, Jacob S, Kinnick TR, et al. Selective angiotensin Ⅱ receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension, 2001,38:884-890.
  • 5Janke J, Engeli S, Gorzelniak K, et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes, 2002,51:1699-1707.
  • 6Julius S, Kjeldsen SE, Weher M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet,2004,363 : 2022-2031.
  • 7Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med, 1996,334:374-381.
  • 8Zanella MT, Kohlmann O Jr, Ribeiro AB. Treatment of obesity, hypertension and diabetes syndrome. Hypertension, 2001,38 : 705- 708.
  • 9Higashiura K, Ura N, Takada T, et al. The effects of an angiotensin-converting enzyme inhibitor and an angiotensin Ⅱ receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens, 2000,13:290-297.
  • 10Togashi N, Ura N, Higashiura K, et al. The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. J Hypertens, 2000,18 : 1905-1910.

共引文献15

农垦医学
2014年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部